Cargando…
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-de...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518534/ https://www.ncbi.nlm.nih.gov/pubmed/23243625 http://dx.doi.org/10.4161/onci.21351 |